28 citations
,
July 2017 in “Expert Review of Anticancer Therapy” This study found that CDK4/6 inhibitors in hormone-positive metastatic breast cancer were linked to increased risks of fatigue, alopecia, and stomatitis compared to placebo.
2 citations
,
November 2025 in “PLoS ONE” This study found that CDK4/6 inhibitors for HR+/HER2- advanced breast cancer are linked to typical adverse events such as fatigue and neutropenia, while also identifying unexpected reactions, highlighting potential safety concerns in their real-world use.
1 citations
,
January 2022 in “Cell Biology International” This study found that altering cyclin-dependent kinase 4 (CDK4) levels in the bulge region of hair follicles affects the balance of stem cell numbers, potentially influencing hair follicle self-renewal and proliferation.
1 citations
,
July 2023 in “Cancers” In this multicentric retrospective study, researchers reported that cutaneous adverse events were common among advanced breast cancer patients treated with cyclin-dependent kinase inhibitors (CDK4/6i), generally mild, and manageable with topical treatments, though in some cases, they led to treatment discontinuation.
April 2010 in “Cancer Research” This study found that altering CDK4 expression in mice affects the population of keratinocyte stem cells, suggesting a correlation with susceptibility to skin papillomas.